Paul Valensi
Overview
Explore the profile of Paul Valensi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
5254
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Valensi P, Benmohammed K, Zerguine M
Diabetes Res Clin Pract
. 2025 Jan;
220:111984.
PMID: 39761874
Although often overlooked sleep apnea has emerged as a significant public health concern. Obstructive sleep apnea (OSA) and diabetes commonly co-exist with a vicious cycle worsening the incidence and severity...
2.
Ojaimi R, Cheisson G, Cosson E, Ichai C, Jacqueminet S, Nicolescu-Catargi B, et al.
Anaesth Crit Care Pain Med
. 2025 Jan;
44(1):101468.
PMID: 39743045
No abstract available.
3.
Valensi P
Cardiovasc Diabetol
. 2024 Sep;
23(1):354.
PMID: 39342254
Prevalence of heart failure (HF) and diabetes are markedly increasing globally. In a population of HF patients, approximately 40% have diabetes which is associated with a more severe HF, poorer...
4.
Seferovic P, Paulus W, Rosano G, Polovina M, Petrie M, Jhund P, et al.
Eur J Heart Fail
. 2024 Jun;
26(9):1893-1903.
PMID: 38896048
The association between type 2 diabetes mellitus (T2DM) and heart failure (HF) has been firmly established; however, the entity of diabetic myocardial disorder (previously called diabetic cardiomyopathy) remains a matter...
5.
Handelsman Y, Anderson J, Bakris G, Ballantyne C, Bhatt D, Bloomgarden Z, et al.
Metabolism
. 2024 Jun;
159:155931.
PMID: 38852020
The spectrum of cardiorenal and metabolic diseases comprises many disorders, including obesity, type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), heart failure (HF), dyslipidemias, hypertension, and...
6.
Valensi P, Jambart S
J Cardiovasc Pharmacol Ther
. 2024 Jun;
29:10742484241258381.
PMID: 38828542
Background: Moxonidine, an imidazoline I receptor agonist, is an effective antihypertensive drug that was shown to improve insulin sensitivity. RAAS-blockers are recommended as first-line therapy in patients with diabetes, alone...
7.
Ibrahim M, Ba-Essa E, Baker J, Cahn A, Ceriello A, Cosentino F, et al.
Diabetes Metab Res Rev
. 2023 Dec;
40(3):e3755.
PMID: 38115715
In the primary care setting providers have more tools available than ever before to impact positively obesity, diabetes, and their complications, such as renal and cardiac diseases. It is important...
8.
Gourdy P, Schiele F, Halimi J, Kownator S, Hadjadj S, Valensi P
Front Cardiovasc Med
. 2023 Oct;
10:1227769.
PMID: 37829695
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity in individuals with type 2 diabetes mellitus (T2DM). Accordingly, several scientific societies have released clinical practice guidelines to...
9.
Fysekidis M, Cosson E, Sabouret P, Takbou K, Sutton A, Charnaux N, et al.
Minerva Cardiol Angiol
. 2023 Jul;
71(6):659-672.
PMID: 37405711
Background: Fast acting insulin analogues are known to improve arterial stiffness. The combination of metformin with insulin represents a widely used therapeutic strategy in diabetes. We hypothesized that insulin treatment...
10.
Valensi P, Berkane N, Pinto S, Sellier N, Soussan M, Nguyen M, et al.
Cardiovasc Diabetol
. 2023 Feb;
22(1):33.
PMID: 36793073
Background: The 2019 guidelines for cardiovascular risk stratification by the European Society of Cardiology and European Association for the Study of Diabetes (ESC-EASD) suggested screening for silent coronary disease in...